SEC Form 4 · accession 0001615774-18-010703
Emmaus Life Sciences, Inc. · EMMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Michal Votruba
Director
Period of report
Oct 8, 2018
Accepted (ET)
Oct 10, 2018 · 9:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822370
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1 | Oct 8, 2018 | A | 144,000 | $1.38 | A | 144,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On October 8, 2018, the Reporting Person was granted 144,000 restricted shares under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. The Reporting Person has assigned all benefits resulting from the grant of restricted common stock and options to RSJ Investments SICAV a.s. acting in respect of its sub-fund (podfond) RSJ Gradus pod fond, RSJ Investments SICAV a.s.